Shlevin Harold H. 4

What Happened
Harold H. Shlevin, a director of Galectin Therapeutics, was granted 60,000 stock options on January 16, 2026. The grant is reported as a derivative acquisition with an acquisition price of $0.00 (total reported $0). The options were issued under the company's 2019 Omnibus Equity Incentive Plan and vest 100% on December 31, 2026.

Key Details

• Transaction date: 2026-01-16 (reported on Form 4 filed 2026-01-21).
• Transaction type/code: Grant/Award (A) — derivative (stock options).
• Quantity: 60,000 options.
• Reported acquisition price: $0.00 (total reported $0).
• Plan: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan (footnote).
• Vesting: 100% vesting on December 31, 2026 (footnote).
• Shares owned after transaction: Not specified in the provided filing.
• Timeliness: Filing was submitted five days after the transaction date; Form 4s are typically due within two business days, so this appears to be filed late.

Context
This was a grant of stock options (a derivative award), not an immediate purchase of shares or an exercise/sale. The options do not result in ownership of common stock until they are vested and exercised. There is no indication in this filing of an immediate exercise or sale (e.g., cashless exercise), and grants can be routine compensation for directors rather than a direct market sentiment signal.